Leerink Partnrs Has Pessimistic View of TMO Q4 Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Research analysts at Leerink Partnrs dropped their Q4 2024 EPS estimates for Thermo Fisher Scientific in a research report issued on Wednesday, October 23rd. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of $5.97 for the quarter, down from their prior forecast of $6.04. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $21.72 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific’s Q1 2025 earnings at $5.59 EPS, Q2 2025 earnings at $5.77 EPS, Q3 2025 earnings at $5.79 EPS, Q4 2025 earnings at $6.67 EPS, FY2025 earnings at $23.81 EPS and FY2026 earnings at $26.49 EPS.

TMO has been the subject of a number of other research reports. Barclays cut their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research note on Wednesday. Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a research report on Monday, October 14th. They set a “buy” rating and a $680.00 price target on the stock. UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th. JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Finally, Stifel Nicolaus dropped their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $649.33.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $554.38 on Friday. The stock has a market capitalization of $211.77 billion, a PE ratio of 34.39, a price-to-earnings-growth ratio of 3.75 and a beta of 0.77. Thermo Fisher Scientific has a 52 week low of $420.21 and a 52 week high of $627.88. The stock has a 50 day moving average price of $606.12 and a 200 day moving average price of $584.21. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company’s revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the business earned $5.69 EPS.

Institutional Investors Weigh In On Thermo Fisher Scientific

Hedge funds have recently made changes to their positions in the stock. Cornerstone Wealth Group LLC boosted its position in Thermo Fisher Scientific by 13.0% in the third quarter. Cornerstone Wealth Group LLC now owns 1,045 shares of the medical research company’s stock valued at $646,000 after buying an additional 120 shares in the last quarter. Oak Harvest Investment Services boosted its holdings in shares of Thermo Fisher Scientific by 5.2% during the 3rd quarter. Oak Harvest Investment Services now owns 5,791 shares of the medical research company’s stock valued at $3,582,000 after acquiring an additional 287 shares in the last quarter. Hudson Valley Investment Advisors Inc. ADV grew its position in Thermo Fisher Scientific by 2.9% during the 3rd quarter. Hudson Valley Investment Advisors Inc. ADV now owns 20,063 shares of the medical research company’s stock worth $12,411,000 after acquiring an additional 556 shares during the last quarter. JFS Wealth Advisors LLC raised its position in Thermo Fisher Scientific by 43.1% in the third quarter. JFS Wealth Advisors LLC now owns 269 shares of the medical research company’s stock valued at $166,000 after purchasing an additional 81 shares during the last quarter. Finally, Diversify Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 11.9% during the third quarter. Diversify Wealth Management LLC now owns 3,549 shares of the medical research company’s stock valued at $2,046,000 after purchasing an additional 378 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $76,420,473.36. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Marc N. Casper sold 6,300 shares of the business’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,548,375.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.